The data presented at the meeting show that multiple administrations of light-activated AU-011 are well-tolerated with no related serious adverse events, severe adverse events or dose-limiting toxicities observed.
Phase 1b/2 clinical data for AU-011, the Company’s lead product candidate for the primary treatment of choroidal melanoma, will be presented in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27-30, 2018, at McCormick Place in Chicago.
Molecular Cancer Therapeutics
Kines R, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang S, Grossniklaus H, Vavvas D, Monks S, MacDougall J, de los Pinos E, Schiller J
Kaliki S and Shields C L